Abstract
Summary An investigation has been undertaken to determine the effects of fenfluramine on glucose tolerance, insulin, fasting lipid and lipoprotein levels, in a series of twenty-five patients suffering from peripheral arterial disease. The results indicate that fenfluramine significantly improved glucose tolerance and that this was not the result of increased insulin production. Small but significant reduction in fasting cholesterol and β lipoprotein levels also occurred in most of the patients. Fenfluramine had no consistent effect on fasting nonesterified fatty acid, glycerides or pre-β lipoproteins.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
